Showing 1 to 8 of 8 results
Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's
Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.
Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's
Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.
Progress
28% Bias Score
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
Progress
44% Bias Score
Eight-Year Gantenerumab Treatment Shows Promise in Delaying Alzheimer's Onset
A small clinical trial of 22 genetically predisposed individuals showed that eight years of treatment with gantenerumab reduced their risk of developing Alzheimer's symptoms by half; however, the drug was later discontinued due to inefficacy in larger trials.
Eight-Year Gantenerumab Treatment Shows Promise in Delaying Alzheimer's Onset
A small clinical trial of 22 genetically predisposed individuals showed that eight years of treatment with gantenerumab reduced their risk of developing Alzheimer's symptoms by half; however, the drug was later discontinued due to inefficacy in larger trials.
Progress
40% Bias Score
Early Amyloid Removal Halves Alzheimer's Risk in Genetic Study
A new study shows that an experimental treatment using amyloid-removing drugs has halved the risk of Alzheimer's symptom onset in a subset of 22 participants with a genetic predisposition to the disease, treated for an average of eight years, raising concerns about funding cuts that could halt the r...
Early Amyloid Removal Halves Alzheimer's Risk in Genetic Study
A new study shows that an experimental treatment using amyloid-removing drugs has halved the risk of Alzheimer's symptom onset in a subset of 22 participants with a genetic predisposition to the disease, treated for an average of eight years, raising concerns about funding cuts that could halt the r...
Progress
48% Bias Score
Lecanemab (Leqembi) Alzheimer Drug Launches in Germany
Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.
Lecanemab (Leqembi) Alzheimer Drug Launches in Germany
Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.
Progress
16% Bias Score
Gantenerumab Halves Alzheimer's Risk in High-Risk Individuals
A Washington University study found that eight years of gantenerumab treatment halved the risk of Alzheimer's in 22 genetically predisposed individuals, highlighting potential for preventative treatment, but longer-term studies and broader trials are needed.
Gantenerumab Halves Alzheimer's Risk in High-Risk Individuals
A Washington University study found that eight years of gantenerumab treatment halved the risk of Alzheimer's in 22 genetically predisposed individuals, highlighting potential for preventative treatment, but longer-term studies and broader trials are needed.
Progress
44% Bias Score
Gantenerumab Halves Alzheimer's Risk in Genetically Predisposed Individuals
A study of 73 adults with a faulty gene (PSEN2) causing nearly certain Alzheimer's found that gantenerumab, an anti-amyloid drug, halved their risk of developing the disease, suggesting that targeting amyloid could prevent Alzheimer's in millions.
Gantenerumab Halves Alzheimer's Risk in Genetically Predisposed Individuals
A study of 73 adults with a faulty gene (PSEN2) causing nearly certain Alzheimer's found that gantenerumab, an anti-amyloid drug, halved their risk of developing the disease, suggesting that targeting amyloid could prevent Alzheimer's in millions.
Progress
40% Bias Score
Faster Tau Protein Buildup Links to Higher Alzheimer's Risk in Women
Groundbreaking research reveals women's higher Alzheimer's risk stems from faster accumulation of tau protein in the brain, particularly in memory and visual processing regions, possibly linked to menopause-related hormonal changes; this discovery impacts Alzheimer's drug trials and necessitates fur...
Faster Tau Protein Buildup Links to Higher Alzheimer's Risk in Women
Groundbreaking research reveals women's higher Alzheimer's risk stems from faster accumulation of tau protein in the brain, particularly in memory and visual processing regions, possibly linked to menopause-related hormonal changes; this discovery impacts Alzheimer's drug trials and necessitates fur...
Progress
40% Bias Score
Showing 1 to 8 of 8 results